Fallen Angels or Value Traps? A Deep Dive into Healthcare Stocks: UnitedHealth and Novo Nordisk

By Zion Zhao | 狮家社小赵

In the current investment climate, healthcare stocks have garnered significant attention due to their precipitous decline relative to the broader equity market. The question on every prudent investor’s mind: Are healthcare stocks such as UnitedHealth Group (UNH) and Novo Nordisk (NVO) truly undervalued opportunities, or are they value traps in disguise? As always, in this essay I aim to provide a comprehensive, fact-checked, and academically grounded analysis of the recent performance of the healthcare sector, drawing on both macro-level data and detailed company-specific fundamentals. Through the lens of financial theory and recent empirical evidence, I will illustrate the nuanced distinctions between “broken stocks” and “broken businesses,” and offer an analytical framework for long-term, risk-managed investment in healthcare equities.

The Healthcare Sector: Cyclical Selloff or Secular Opportunity?

The healthcare sector, as represented by the Health Care Select Sector SPDR Fund (XLV), has experienced a marked decline compared to the S&P 500 Index (SPY). As of mid-2025, XLV/SPY is trading at a 24-year low, a level not seen since 2000. Valuation metrics corroborate this: the price-to-earnings (P/E) ratio of the healthcare sector is at a 30-year low relative to the S&P 500, signaling significant underperformance (S&P Global, 2024; BlackRock, 2024). Net fund flows have reflected widespread pessimism, with both institutional and retail investors registering the largest outflows in over two decades (Bloomberg, 2024).

Historically, such periods of underperformance are often followed by mean reversion, especially in secular growth industries like healthcare (Fama & French, 2007). The underlying thesis for a rebound rests on the premise that healthcare demand is largely inelastic, driven by demographic trends, increasing prevalence of chronic diseases, and ongoing innovation (World Health Organization [WHO], 2024).

Subsector Analysis: Divergence Within Healthcare

Contrary to the headline performance, not all healthcare subsectors have been equally affected. For example, medical devices (tracked by the IHI ETF) and certain niche healthcare providers (such as HCA Healthcare and Idexx Laboratories) have remained resilient, even posting gains amid sector-wide weakness. Pharmaceuticals (XPH ETF) have been roughly flat, while managed care organizations (MCOs), represented by the IHF ETF, have borne the brunt of the selloff due to unique industry headwinds (Morningstar, 2025).

“Broken Stocks” vs. “Broken Businesses”: The Investment Framework

One of the most important analytical distinctions for value investors is whether a company’s share price decline reflects transient sentiment (a “broken stock”) or fundamental deterioration (a “broken business”) (Graham & Dodd, 1934; Greenblatt, 2010).

• Broken Stock: Shares are down due to market overreaction, but the underlying business remains robust.

• Broken Business: The company has lost its competitive advantage, with deteriorating financials, eroded economic moat, and persistent losses.

Historical case studies such as Meta Platforms (formerly Facebook) and Netflix illustrate how “broken stocks” can rebound dramatically once investor sentiment normalizes, provided the core business metrics remain intact (Damodaran, 2022). Conversely, companies like Intel serve as reminders that without a durable economic moat and profitable growth, recovery may not materialize.

UnitedHealth Group (UNH): Short-Term Turbulence, Long-Term Resilience?

Fundamental Performance

UnitedHealth Group, the largest health insurer in the U.S., exemplifies the conundrum facing many MCOs. Despite a 62% decline in share price from its recent peak, the business fundamentals remain broadly robust. UNH continues to grow revenue—reporting a 16% year-on-year increase in the latest quarter (UnitedHealth Group, 2024)—and maintains industry-leading profitability, albeit with slowing earnings growth.

Its economic moat is validated by unmatched scale (serving over 50 million lives), high switching costs, and vertical integration through its Optum subsidiary. These factors result in high barriers to entry and sustainable margins over the cycle (Morningstar, 2025).

Current Challenges

The two primary headwinds are:

1. Department of Justice (DOJ) Investigation: The DOJ is probing allegations of Medicare Advantage overbilling by UNH. While such investigations can be disruptive, historical precedent suggests limited long-term impact—most notably in the case of Wells Fargo and Meta Platforms, where large fines did not impede eventual business recovery or stock performance (U.S. Department of Justice, 2024; CNBC, 2023).

2. Rising Medical Loss Ratio (MLR): The more pressing concern is the surge in UNH’s MLR from 80% to 89%. This reflects both post-pandemic catch-up in elective procedures and underpriced premiums amid escalating healthcare costs. While earnings per share (EPS) guidance for 2025 has been slashed to $16 (from $20 in 2023), management anticipates that premium repricing in 2026–2027 will restore profitability to historical norms (UnitedHealth Group, 2024; Wall Street Journal, 2025).

Valuation and Margin of Safety

Utilizing a discounted net income model, conservative growth assumptions (FactSet consensus) yield an intrinsic value of $330/share (My personal absolute ultimate bear case DCF: FCF: $218.12, EPS: $200.99, Adj Div: $180.89)  for UNH—well above the prevailing market price. If long-term growth reverts to the historical mean (~10.5%), the intrinsic value may reach $410–$473/share, offering a substantial margin of safety (FactSet, 2025; Damodaran, 2024). Even under pessimistic scenarios, the stock appears undervalued by 20–40%.

Risk Considerations

Investors should recognize that price recoveries may not be immediate, and that short-term volatility can persist, especially if sector outflows continue or regulatory risks escalate. However, empirical evidence supports the thesis that patient, long-term investors in businesses with durable economic moats and stable cash flows are rewarded over time (Fama & French, 2007; Greenblatt, 2010).

Novo Nordisk (NVO): Structural Growth Amid Competitive Pressures

Business Overview

Novo Nordisk is a global leader in diabetes and obesity pharmaceuticals, holding a 70% share in obesity drugs and 33% in diabetes care by revenue (Novo Nordisk, 2024). Its blockbuster drugs, Wegovy (semaglutide) and Ozempic, have become household names due to strong efficacy and rising global incidence of diabetes.

Recent Headwinds

NVO shares have fallen 68% from all-time highs, driven by two main concerns:

1. Lowered Growth Guidance: Management revised revenue growth forecasts downward from 13–21% to 8–14%, and profit growth from 16–24% to 10–16%—primarily due to increasing competition from Eli Lilly and compounded generics (Novo Nordisk, 2024).

2. Political and Pricing Pressures: Regulatory signals, including U.S. initiatives to curb drug prices, have heightened uncertainty over future margins (Kaiser Family Foundation, 2025).

Is Novo Nordisk a Broken Stock or Broken Business?

Despite management’s cautious tone and market share concerns, NVO’s core financials remain healthy. Revenues and net income continue to grow, and the company maintains a wide economic moat underpinned by high barriers to entry, brand loyalty, and economies of scale (Morningstar, 2025).

A critical macro tailwind remains: global diabetes prevalence is forecast to rise from 551 million in 2024 to 783 million by 2045, providing a long runway for growth regardless of market share shifts (International Diabetes Federation [IDF], 2024).

Intrinsic Value

Discounted free cash flow analysis (using FactSet and company guidance) estimates NVO’s intrinsic value at $89/share(My personal absolute ultimate bear case DCF: FCF: $22.27, EPS: $31.04, Adj Div: $27.89) , nearly double its market price of $48 (FactSet, 2025). Even under conservative (doomsday) assumptions, intrinsic value remains above $68, suggesting an attractive risk-reward profile.

Management and Strategic Considerations

While recent C-suite turnover and competitive pressure warrant monitoring, the company’s entrenched leadership in a structurally growing market implies resilience. However, prudent investors should temper expectations for hyper-growth and model more moderate long-term expansion.

Conclusion: Sector Outlook and Investment Implications

The recent selloff in healthcare stocks—especially among managed care organizations and major pharmaceutical innovators—reflects a complex interplay of cyclical cost headwinds, regulatory uncertainty, and investor risk aversion. However, an analysis grounded in fundamentals and economic theory suggests that these declines are characteristic of “broken stocks,” not “broken businesses,” in the cases of UnitedHealth Group and Novo Nordisk.

For long-term, disciplined investors, current valuations present compelling opportunities with substantial margins of safety, provided that investments are made within the context of personal financial objectives, risk tolerance, and a commitment to due diligence.

---

Discover Real Opportunity Beyond the Headlines – Engage an Advisor Who Sees the Full Picture

In a world where financial markets can swing between “fallen angels” and generational opportunities, true wealth is built on insight, discipline, and strategic diversification. As a seasoned Real Estate agent based in Singapore, I bring you more than transactional expertise—I offer a unique perspective honed by years of macroeconomic analysis, global asset allocation, and a proven track record in navigating equity markets.

Every day, I dedicate hours to researching, writing, and critically analyzing not just real estate trends, but also the complex interplay between international geopolitics, economic cycles, and alternative asset classes. My recent essay, “Fallen Angels or Value Traps? A Deep Dive into Healthcare Stocks,” reflects the same commitment to rigorous due diligence and forward-thinking strategy that I apply for my clients—whether you are seeking prime property for investment, family office migration, or educational relocation (陪读家长，留学，家办).

In today’s dynamic environment, it is vital to partner with an advisor who:

• Stays Ahead of Global Trends: I keep abreast of shifting macroeconomic currents, policy developments, and sector-specific opportunities, so you benefit from informed, data-driven decisions.

• Practices Relentless Due Diligence: I invest significant time each day analyzing markets and crafting research-backed essays, ensuring every recommendation is grounded in facts, not hype.

• Understands Diversification: While equities and alternative assets can be volatile, real estate—especially Singapore property—offers stability, strong capital appreciation, and rental yields that act as a dividend-like income stream.

For international investors, ultra-high-net-worth individuals, and institutional clients from China, Southeast Asia, and around the globe, Singapore’s property market stands as a beacon of resilience, transparency, and long-term growth. Including real estate in your portfolio not only reduces volatility, but also anchors your wealth in one of the world’s most robust, investor-friendly economies.

Let’s connect for a confidential, tailored discussion on how to leverage Singapore’s unique advantages for your family, investment goals, or institutional strategy.
Contact me today and experience the difference that rigorous research, global acumen, and unwavering integrity can make.

Your gateway to Singapore’s finest opportunities—where real estate meets real insight.

---

References

BlackRock. (2024). Healthcare sector outlook: Risks and opportunities. Retrieved from https://www.blackrock.com/us/individual/insights/healthcare-sector-outlook

Bloomberg. (2024, June). Healthcare stocks suffer largest outflows since 2000. Retrieved from https://www.bloomberg.com/markets

Damodaran, A. (2022). Narrative and Numbers: The Value of Stories in Business. Columbia University Press.

Damodaran, A. (2024). Equity risk premiums and market outlook 2024. Retrieved from https://pages.stern.nyu.edu/~adamodar/

FactSet. (2025). Analyst consensus estimates: UnitedHealth Group and Novo Nordisk. Retrieved from https://www.factset.com/

Fama, E. F., & French, K. R. (2007). Disagreement, tastes, and asset prices. Journal of Financial Economics, 83(3), 667-689. https://doi.org/10.1016/j.jfineco.2006.01.003

Graham, B., & Dodd, D. L. (1934). Security Analysis. McGraw-Hill.

Greenblatt, J. (2010). The Little Book That Still Beats the Market. Wiley.

International Diabetes Federation. (2024). IDF Diabetes Atlas (11th ed.). Retrieved from https://diabetesatlas.org/

Kaiser Family Foundation. (2025). Prescription drug spending and policy. Retrieved from https://www.kff.org/

Morningstar. (2025). Equity Analyst Reports: UnitedHealth Group and Novo Nordisk. Retrieved from https://www.morningstar.com/

Novo Nordisk. (2024). Annual Report 2023. Retrieved from https://www.novonordisk.com/investors/annual-report.html

S&P Global. (2024). Healthcare sector performance and valuation. Retrieved from https://www.spglobal.com/

UnitedHealth Group. (2024). Quarterly Earnings Report Q2 2025. Retrieved from https://www.unitedhealthgroup.com/investors.html

U.S. Department of Justice. (2024). Justice Department investigates Medicare Advantage fraud. Retrieved from https://www.justice.gov/

Wall Street Journal. (2025, July). Health insurers seek big rate increases amid cost pressures. Retrieved from https://www.wsj.com/

World Health Organization. (2024). Global health and aging: Policy implications. Retrieved from https://www.who.int/